Annual report [Section 13 and 15(d), not S-K Item 405]

Significant Accounting Policies (Narrative) (Details)

v3.26.1
Significant Accounting Policies (Narrative) (Details)
1 Months Ended 12 Months Ended
Oct. 31, 2024
USD ($)
Jul. 31, 2016
shares
Dec. 31, 2025
USD ($)
segment
subsidiary
shares
Dec. 31, 2024
Significant Accounting Policies        
Number of subsidiaries | subsidiary     0  
Number of operating segments | segment     1  
Number of Reportable Segments | segment     1  
Estimated useful life     5 years  
Class A common stock and Class A preferred stock, rights to convert to number of common shares | shares     1,461  
Accumulated other comprehensive loss | $     $ 0  
Existing Warrants        
Significant Accounting Policies        
Amount of deemed dividend | $ $ 7,800,000      
Fortress Biotech, Inc        
Significant Accounting Policies        
Percentage of fully diluted equity     2.50% 2.50%
Fortress Biotech, Inc | Class A Preferred Shares        
Significant Accounting Policies        
Preferred stock dividends issued (in shares) | shares   250,000    
Percentage of fully diluted equity   2.50%